CareDx (CDNA) Projected to Post Earnings on Tuesday

CareDx (NASDAQ:CDNA) is expected to be issuing its Q1 2026 results after the market closes on Tuesday, April 28th. Analysts expect the company to announce earnings of $0.13 per share and revenue of $102.2870 million for the quarter. Parties are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Tuesday, April 28, 2026 at 4:30 PM ET.

CareDx (NASDAQ:CDNA) last released its earnings results on Tuesday, February 24th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.12). The firm had revenue of $108.39 million for the quarter, compared to the consensus estimate of $102.76 million. CareDx had a negative return on equity of 6.50% and a negative net margin of 5.65%.The company’s revenue was up 25.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.18 EPS. On average, analysts expect CareDx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

CareDx Stock Down 0.6%

CDNA stock opened at $21.29 on Tuesday. The company has a market cap of $1.09 billion, a P/E ratio of -53.23 and a beta of 2.54. CareDx has a twelve month low of $10.96 and a twelve month high of $23.24. The business has a fifty day moving average of $18.31 and a 200-day moving average of $17.96.

Insider Buying and Selling

In related news, CEO John Walter Hanna, Jr. sold 10,282 shares of the company’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $21.12, for a total value of $217,155.84. Following the completion of the sale, the chief executive officer owned 676,475 shares in the company, valued at approximately $14,287,152. This represents a 1.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 29,762 shares of company stock valued at $629,321 in the last ninety days. Corporate insiders own 4.40% of the company’s stock.

Institutional Investors Weigh In On CareDx

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD increased its holdings in CareDx by 1.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 39,218 shares of the company’s stock valued at $739,000 after purchasing an additional 711 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in CareDx by 4.8% in the second quarter. The Manufacturers Life Insurance Company now owns 27,742 shares of the company’s stock valued at $542,000 after purchasing an additional 1,280 shares during the last quarter. Quarry LP bought a new stake in CareDx in the fourth quarter valued at about $25,000. Franklin Resources Inc. increased its holdings in shares of CareDx by 3.8% in the fourth quarter. Franklin Resources Inc. now owns 103,703 shares of the company’s stock worth $1,954,000 after acquiring an additional 3,774 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in shares of CareDx by 120.6% in the second quarter. Tower Research Capital LLC TRC now owns 7,608 shares of the company’s stock worth $149,000 after acquiring an additional 4,160 shares in the last quarter.

Wall Street Analysts Forecast Growth

CDNA has been the subject of a number of recent research reports. Weiss Ratings downgraded CareDx from a “hold (c-)” rating to a “sell (d)” rating in a research report on Friday, February 27th. BTIG Research boosted their target price on CareDx from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Wall Street Zen downgraded CareDx from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Craig Hallum downgraded CareDx from a “buy” rating to a “hold” rating and set a $26.00 price objective for the company. in a report on Tuesday, January 6th. Finally, Wells Fargo & Company upped their price objective on CareDx from $18.00 to $21.00 and gave the company an “equal weight” rating in a report on Wednesday, February 25th. Two investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, CareDx presently has a consensus rating of “Hold” and a consensus target price of $27.60.

CareDx Company Profile

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non?invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post?transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor?derived cell?free DNA assay used primarily in kidney transplant monitoring.